Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2023 > Vol 4, №3 (2023) > The new perspective on the pathogenesis of endometrial polyps involving the use of mononuclear cells

The new perspective on the pathogenesis of endometrial polyps involving the use of mononuclear cells

Mekan R. Orazov, Lyudmila M. Mikhaleva, Olga А. Poymanova, Irina A. Mullina

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Endometrial polyps are often complicated by abnormal bleeding and often turn into malignant forms. Even with an asymptomatic course and no complaints, endometrial polyps can be the cause of female infertility. Despite effective diagnosis and polypectomy with curettage, the problem persists due to the high recurrence rate of the disease. The significant prevalence of endometrial polyposis and relapses after the intervention make it necessary to look for additional opportunities to reduce recurrent incidence in the population of women of childbearing age. 
Aim – to study the potential of using mononuclear cells as a means of preventing recurrence of endometrial polyps. 
Methods. To achieve this goal, a literature search was performed in the PubMed and Google Scholar libraries with a selection of articles on the specified topic. 
Results. Articles describing the use of native or modified human mononuclear cells as a means of suppressing tumor activity and enhancing antitumor immunity were analyzed. 
Conclusions. The main directions in antitumor therapy based on the use of peripheral blood mononuclear cells are: 1) the use of lymphocytic concentrate; 2) blocking the checkpoints of the immune system, leading to an increase in the antitumor effect; 3) genetic modification of lymphocytes, enhancing their tumoricidal properties. 
Key words: polyp, endometrium, mononuclears, proliferation, cancer

About the Author

Mekan R. Orazov1, Lyudmila M. Mikhaleva2, Olga А. Poymanova1, Irina A. Mullina1

1 Patrice Lumumba Peoples' Friendship University of Russia, Moscow, Russia

2 Avtsyn Research Institute of Human Morphology of Petrovsky National Research Centre of Surgery, Moscow, Russia

References

1. Макаренко Т.А., Ключаров И.В., Кузнецова Д.Е. и др. Современный взгляд на диагностику и лечение полипов эндометрия. Гинекология. 2020; 6: 46–55. [Makarenko T.A., Kliucharov I.V., Kuznetsova D.E. i dr. Sovremennyi vzgliad na diagnostiku i lechenie polipov endometriia. Ginekologiia. 2020; 6: 46–55 (in Russian).] 
2. Van Den Bosch T, Verbakel JY, Valentin L et al. Typical ultrasound features of various endometrial pathologies described using International Endometrial Tumor Analysis (IETA) terminology in women with abnormal uterine bleeding. Ultrasound Obstet Gynecol 2021; 57 (1): 164–72. DOI: 10.1002/uog.22109 
3. Sasaki LMP, Andrade KRC, Figueiredo ACMG et al. Factors Associated with Malignancy in Hysteroscopically Resectes Endometrial Polyps: A Systematic Recview and Meta-Analysis. J Min Invasive Gynecol 2018; 25 (5): 777–85. DOI: 10.1016/j.jmig.2018.02.004 
4. Jee BC, Jeong HG. Management of endometrial in infertile women: A mini-review. Clin Exp Reprod Med 2021; 48 (3): 198–202. DOI: 10.5653/cerm.2020.04119 
5. Кузьо И.А., Евсеев А.В., Баударбекова М.М. Иммуногистохимическая характеристика процессов пролиферации и апоптоза в простой гиперплазии эндометрия и гиперпластических эндометриальных полипах. Вестн. РГМУ. 2015; 2: 20. [Kuz'o I.A., Evseev A.V., Baudarbekova M.M. Immunogistokhimicheskaia kharakteristika protsessov proliferatsii i apoptoza v prostoi giperplazii endometriia i giperplasticheskikh endometrial'nykh polipakh. Vestn. RGMU. 2015; 2: 20 (in Russian).] 
6. Савельева Г.М., Бреусенко В.Г., Карева Е.Н. и др. Новая стратеги поиска гормональной терапии пролиферативных процессов эндометрия у пациенток в постменопаузе. Вестн. РГМУ. 2022; 3: 44–52. [Savel'eva G.M., Breusenko V.G., Kareva E.N. i dr. Novaia strategi poiska gormonal'noi terapii proliferativnykh protsessov endometriia u patsientok v postmenopauze. Vestn. RGMU. 2022; 3: 44–52 (in Russian).] 
7. Волчок Н.В. Современные аспекты развития полипов эндометрия в репродуктивном периоде. Мед. журнал. 2014; 1 (47): 56–8. [Volchok N.V. Sovremennye aspekty razvitiia polipov endometriia v reproduktivnom periode. Med. zhurnal. 2014; 1 (47): 56–8 (in Russian).] 
8. Волошин В.В. Экспрессия рецепторов половых гормонов, Ki 67, bcl-2, p53 в полипах эндометрия с атипической гиперплазией желез. Известия высших учебных заведений. Северо-Кавказский регион. Естественные науки. 2006; S15: 36–40. [Voloshin V.V. Ekspressiia retseptorov polovykh gormonov, Ki 67, bcl-2, p53 v polipakh endometriia s atipicheskoi giperplaziei zhelez. Izvestiia vysshikh uchebnykh zavedenii. Severo-Kavkazskii region. Estestvennye nauki. 2006; S15: 36–40 (in Russian).] 
9. Гришкина А.А., Чистякова Г.Н., Ремизова И.И., Мелкозерова О.А. Рецептивность эндометрия и экспрессия факторов апоптоза и пролиферации в эндометрии женщин с гиперплазией и бесплодием. Вестн. ВолгГМУ. 2019; 4 (72): 37–9. [Grishkina A.A., Chistiakova G.N., Remizova I.I., Melkozerova O.A. Retseptivnost' endometriia i ekspressiia faktorov apoptoza i proliferatsii v endometrii zhenshchin s giperplaziei i besplodiem. Vestn. VolgGMU. 2019; 4 (72): 37–9 (in Russian).] 
10. Чернуха Г.Е., Иванов И.А., Думановская М.Р. Возможности терапии и вторичной профилактики полипов эндометрия. Акушерство и гинекология. 2020; 8 (2): 97–102. DOI: 10.24411/2303- 9698- 2020-12009 [Chernukha G.E., Ivanov I.A., Dumanovskaia M.R. Vozmozhnosti terapii i vtorichnoi profilaktiki polipov endometriia. Akusherstvo i ginekologiia. 2020; 8 (2): 97–102. DOI: 10.24411/2303-9698- 2020- 12009 (in Russian).] 
11. Vahdat M, Mousavi AS, Kaveh M et al. Hysteroscopic polypectomy with endometrial resection preventing the recurrence of endometrial polyps: A single-blinded randomized clinical trial. Caspian J Intern Med 2022; 13 (2): 393–7. DOI: 10.22088/cjim.13.2.393 
12. Lu MY, Li XH, Niu JL, Liu B. LIN28B Polymorphisms Confer a Higher Postoperative Recurrence Risk in Reproductive-Age Women with Endometrial Polyps. Dis Markers 2022: 4824357. DOI: 10.1155/ 2022/4824357 
13. Яндовицкая М.С., Сазонова В.А., Тохтамишян А.К., Говоров М.С. Профилактика рецидива полипов эндометрии. 5-я итоговая научная сессия молодых ученых РостГМУ: сборник материалов, 11 апреля 2018 г., Ростов-на-Дону. Ростов н/Д: Изд-во РостГМУ, 2018. [Iandovitskaia M.S., Sazonova V.A., Tokhtamishian A.K., Govorov M.S. Profilaktika retsidiva polipov endometrii. 5-ia itogovaia nauchnaia sessiia molodykh uchenykh RostGMU: sbornik materialov, 11 aprelia 2018 g., Rostov-na-Donu. Rostov n/D: Izd-vo RostGMU, 2018 (in Russian).] 
14. Михельсон А.Ф., Феоктистова Т.Е., Лебеденко Е.Ю. и др. Влияние комбинации эстрадиола валерата и диеногеста на частоту рецидивов гормончувствительных полипов эндометрия. Гинекология. 2016; 7 (124): 27–31. [Mikhel'son A.F., Feoktistova T.E., Lebedenko E.Iu. i dr. Vliianie kombinatsii estradiola valerata i dienogesta na chastotu retsidivov gormonchuvstvitel'nykh polipov endometriia. Ginekologiia. 2016; 7 (124): 27–31 (in Russian).] 
15. Bukovsky A. Involvement of blood mononuclear cells in the infertility, age-associated diseases and cancer treatment. World J Stem Cells 2016; 8 (12): 399–427. DOI: 10.4252/wjsc.v8.i12.399 
16. Lin HD, Fong CY, Biswas A, Bongso A. Hypoxic Wharton’s Jelly Stem Cell Conditioned Medium Induces Immunogenic Cell Death in Limphoma Cells. Stem Cells Int 2020; 4670948. DOI: 10.1155/2020/4670948 
17. Зайцев С.А. Оценка цитотоксической активности мононуклеарных клеток онкологических больных In Vitro. Российский биотерапевтический журнал. 2016; 1 (15): 40–1. [Zaitsev S.A. Otsenka tsitotoksicheskoi aktivnosti mononuklearnykh kletok onkologicheskikh bol'nykh In Vitro. Rossiiskii bioterapevticheskii zhurnal. 2016; 1 (15): 40–1 (in Russian).] 
18. Bukovsky A, Caudle MR. Former Effective Immunotherapy without Adverse Events of Inoperable Epithelial Ovarian Cancers and a Prospect for the Immune Prophylaxis. J Gyn Res 2018; 4 (1): 102. 
19. Боженко В.К., Шкопоров А.Н., Мишкин А.М., Солодкий В.А. Разработка мономолекулярного химерного рецептора Т-лимфоцитов человека для использования в лечении опухолей, положительных к раково-эмбриональному антигену. Успехи молекулярной онкологии. 2016; 3 (4): 70–1. [Bozhenko V.K., Shkoporov A.N., Mishkin A.M., Solodkii V.A. Razrabotka monomolekuliarnogo khimernogo retseptora T-limfotsitov cheloveka dlia ispol'zovaniia v lechenii opukholei, polozhitel'nykh k rakovo-embrional'nomu antigenu. Uspekhi molekuliarnoi onkologii. 2016; 3 (4): 70–1 (in Russian).] 
20. Choi Y, Shi Y, Haymaker CL et al. T-cell agonists in cancer immunotherapy. J Immunother Cancer 2020; 8 (2): e000966. DOI: 10.1136/jitc-2020-000966 
21. Smith-Garvin JE, Koretzky GA, Jordan MS. T Cell Activation. Annu Rev Immunol 2009; 27: 591–619. DOI: 10.1146/annurev.immunol.021908.132706
22. Mchayleh W, Bedi P, Sehgal R et al. Chimeric antigen receptor T-cells: the future is now. J Clin Med 2019; 8: 207. DOI: 10.3390/jcm8020207 
23. Curti BD, Kovacsovics-Bankowski M, Morris N et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Clinical Trial 2013; 73 (24): 7189–98. DOI: 10.1158/0008-5472 
24. Sznol M, Hodi FS, Margolin K et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (PTS) with advanced cancer (Ca). J Clin Oncol 2008; 26: 3007. DOI: 10.1200/jco.2008.26.15_suppl.3007 
25. Riccardi C, Ronchetti S, Nocentini G. Glucocorticoid-induced TNFRrelated gene (GITR) as a therapeutic target for immunotherapy. Expert Opin Ther Targets 2018; 22 (9): 783–97. DOI: 10.1080/ 14728222.2018.1512588 
26. Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012; 24 (2): 217–24. DOI: 10.1016/j.coi.2011.12.011 
27. Denlinger CS, Infante JR, Aljumaily R et al. A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors. Ann Oncol 2018; 29: viii411. DOI: 10.1093/annonc/mdy288.027 
28. Chen Q, Mo L, Cai X et al. Icos signal facilitates FOXP3 transcription to favor suppressive function of regulatory T cells. Int J Med Sci 2018; 15: 666–73. DOI: 10.7150/ijms.23940 
29. Tu JF, Ding YH, Ying XH et al. Regulatory T cells, especially ICOS(+) FOXP3(+) regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep 2016; 6: 35056. DOI: 10.1038/srep35056 
30. Quaratino S, Sainson R, Thotakura A et al. A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies. J Clin Oncol 2019; 37: TPS2644–TPS. DOI: 10.1200/JCO.2019.37.15_suppl.TPS2644 
31. Wylie B, Macri C, Mintern JD, et al. Dendritic cells and cancer: from biology to therapeutic intervention. Cancers 2019; 11: 521. DOI: 10.3390/cancers11040521 
32. Zitvogel L, Galluzzi L, Kepp O et al. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15: 405–14. DOI: 10.1038/nri3845 
33. Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol 2010; 40: 2667–76. DOI: 10.1002/eji.201040839 
34. Ray A, Das DS, Song Y et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia 2015; 29: 1441–4. DOI: 10.1038/leu.2015.11 
35. Martins KAO, Bavari S, Salazar AM. Vaccine adjuvant uses of polyIC and derivatives. Expert Rev Vaccines 2015; 14: 447–59. DOI: 10.1586/14760584.2015.966085 
36. Sabbatini P, Tsuji T, Ferran L et al. Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients. Clin Cancer Res 2012; 18: 6497–508. DOI: 10.1158/1078-0432.CCR-12-2189

For citation:Orazov M.R., Mikhaleva L.M., Poymanova O.А., Mullina I.A. The new perspective on the pathogenesis of endometrial polyps involving the use of mononuclear cells. Clinical review for general practice. 4 (3): 41–46. DOI: 10.47407/kr2023.4.3.00221


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

Scopus
doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru